Research · 8 min read
Menopause equity: why so many women still fall through the cracks, and how to get the care you deserve
Menopause is a normal transition, but getting timely, informed care for it can still be a matter of luck. Whether a clinician was trained to recognize the symptoms, whether anyone screens for them, whether a health plan covers evaluation and treatment, and whether it feels acceptable to bring the subject up in a visit or at work all shape what happens next.
The American Medical Women's Association has a name for closing those gaps: menopause equity. On November 18, 2026, AMWA highlighted a position paper on the subject, written by members of its Gender Equity Task Force and published July 3, 2026, in Frontiers in Reproductive Health. The paper is not a treatment guideline, and it is not a test that can tell you whether you are in perimenopause or menopause. It is an argument that menopause should be treated as a health-equity issue, and it names the barriers the authors say still get in the way.
This article is for education. It is not medical advice and not legal advice. What follows walks through those gaps, notes what is changing, and offers a practical checklist for a visit.
The gaps AMWA names
In the paper's abstract, the authors write that "insufficient clinician training, lack of standardized screening, limited insurance coverage, and cultural stigma continue to hinder comprehensive and unbiased care." In the body, they also point to historical research gaps and to "persistent gender bias in health messaging and research priorities." The strategies they offer are to integrate menopause education into medical training, expand insurance coverage for menopause-related services, increase research funding, normalize menopause in the workplace, launch public-health campaigns, and promote culturally competent care. Those five problems — training, screening, coverage, research, and stigma — also suggest questions worth bringing to a visit.
Training. AMWA says clinician education on menopause is insufficient and calls for comprehensive, evidence-based training for people still in training and for those already in practice. The paper does not quantify how many hours a typical medical school or residency now spends on menopause, and we are not inferring a number. The practical point is simpler: it is reasonable to ask a clinician how often they care for people in perimenopause and menopause, and how they approach evaluation.
Screening. The authors cite a lack of standardized screening and staging, and they say patients and clinicians often receive inconsistent information. Symptoms can be underdiagnosed or attributed to something else, and opportunities for earlier support can be missed. AMWA also asks insurers to cover menopause-related preventive screenings and related services. What any one person actually needs, and whether a particular test is useful, is a clinical decision. Menopause is often assessed from a history and a visit, not from a single lab result.
Coverage. Limited insurance coverage is one of the gaps named in the abstract. AMWA's written strategy is to expand coverage for menopause-related services under all insurance plans, including evaluation, evidence-based treatment, and related support. What a given plan covers still depends on the policy, on medical-necessity and prior-authorization rules, and on a conversation with the insurer or a benefits office. We walked through recently enacted and pending state coverage measures, and some general questions to ask an insurer, in our November 18 post on menopause care in state law. That post also noted a federal survey finding that, among women ages 40 to 60 who had menopausal symptoms in the past 12 months, only about one in six were currently taking a prescription for them.
Research. The paper treats thin evidence as both a cause of uneven care and a policy problem. AMWA calls for more funding and for studies that include menopause alongside chronic disease and other reproductive transitions. That is not something a single visit can fix, but it helps explain why two thoughtful clinicians can still give you different answers, and why shared decision-making matters.
Stigma. AMWA argues that cultural stigma, including caricatures of menopause in popular media, can discourage people from seeking care or asking for workplace adjustments. The authors want menopause treated as a legitimate health concern rather than a punchline. If a prior visit dismissed your symptoms, that history is worth putting on the table at the next one.
What's changing
In the United States, state lawmakers have been moving on insurance coverage, public education, and workplace accommodations. Some of that work is already in statute; some of it is still pending. We verified Pennsylvania and Illinois status, as of November 18, 2026, in Menopause care is going mainstream in state law. This article does not repeat that bill-by-bill rundown, and it is not a prediction about what any legislature will pass. Bill and law status can change, and what a plan covers still depends on the final text of any law and on your own policy.
Academic posts are another part of the shift. On November 18, 2026, the University of British Columbia Faculty of Medicine and BC Women's Health Foundation announced the UBC Professorship in Midlife and Mature Women's Health, held jointly by Dr. Lori Brotto, a registered clinical psychologist and UBC Distinguished Professor, and Dr. Kelsey Mills, an obstetrician-gynecologist. Both the university's news post and the foundation's GlobeNewswire release describe the role as the first of its kind in British Columbia. It was created with the Women's Health Research Institute and BC Women's Hospital, and it is meant to connect specialized menopause care, research, and education for health-care providers. Cally Wesson, the foundation's president and CEO, said philanthropy and donor investment in research and leadership are helping build a stronger future for menopause care in British Columbia.
Clinical guidance is moving too. In October 2026, the American College of Obstetricians and Gynecologists published expanded recommendations on menopause-related vasomotor, sleep, and mood symptoms, Clinical Practice Guideline No. 13. ACOG's October 15 news release says the decision to start hormone therapy should be based on shared decision-making, taking into account symptoms, age, medical history, baseline risks of cardiovascular disease, breast cancer, and blood clots, and the person's own goals. If hormone therapy is selected, ACOG recommends starting it before age 60 or within 10 years of the start of spontaneous menopause, in people without contraindications. The release also reviews nonhormonal options for people who cannot or prefer not to use hormones. A coauthor, Dr. Robert P. Kauffman, put it this way: "Hormone therapy can be a great option—and in many cases, the best option—but may not be appropriate or helpful for every person experiencing menopausal symptoms."
Some later coverage has used a shorter label. A November 17 WBUR Here & Now report and a November 18 Penn State Health News Medical Minute both described the guidance as recommending hormone therapy as a "first-line" treatment for hot flashes and other menopause symptoms. That phrase does not appear in ACOG's October 15 press release. We are attributing it to those reports, not treating it as ACOG's own wording. AMWA's paper, a perspective rather than a treatment guideline, uses another formulation: "Hormone therapy remains the most effective treatment for vasomotor symptoms," while stressing that care should be individualized. We walked through ACOG's public recommendations in more detail in an earlier post.
Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. Who should not take it, and how timing and age factor in, are questions for a clinician. We have written in more detail about who shouldn't take hormone therapy and timing and age.
A practical checklist for getting evaluated
You do not need to wait for a law, a professorship, or a guideline update to prepare for a visit. None of the steps below diagnoses perimenopause or menopause, and none of them is a treatment plan. They are a way to make a short appointment more useful.
-
Write down what you have noticed, and for how long. Include hot flashes or night sweats, sleep, mood, bleeding or cycle changes, pain with sex, urinary symptoms, and joint or muscle pain, even if you are not sure they are related. A month-long log may help; we described a 16-item research scale that asks about the past 30 days in a recent post on perimenopause symptoms. That scale is a checklist, not a test that can tell you you are in perimenopause, and the same symptoms can have other causes.
-
Bring your history. Surgeries, cancers, blood clots, migraine, medications, and what you have already tried all help a clinician decide what is reasonable to consider. If a previous visit dismissed your symptoms, say so.
-
Ask how often the clinician cares for people in perimenopause and menopause, and how they usually evaluate symptoms. You are not auditing a medical school curriculum; you are finding out whether this is a regular part of their practice.
-
Ask what evaluation they recommend, and why. If a test is proposed, it is fair to ask what it would change.
-
Ask about both hormonal and nonhormonal options, and whether hormone therapy is appropriate for you given your history. Ask how they would think about timing, and when they would want to reassess. ACOG's public guidance puts those decisions in a shared conversation, not a single default.
-
If cost or coverage will affect what you can do, ask your insurer or benefits office some general questions: whether evaluation and treatment of menopause symptoms are covered, whether a prior authorization is required, and what your cost-sharing would be. Our November 18 state-law post includes a short list of those consumer questions. What a plan covers is a question for the insurer, not a statement about any one clinic.
-
If the visit does not leave you with a clear plan, a second opinion, or a clinician who does more menopause care, may be reasonable.
If you are thinking about harming yourself or ending your life, or you are in emotional crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or chat at 988lifeline.org. It is free, confidential and available 24/7. If you or someone else is in immediate danger or having a medical emergency, call 911.
Where Kindr fits
At Kindr Health, menopause and midlife care is clinician-led. If you are trying to sort out symptoms or whether hormone therapy or a nonhormonal option belongs in the conversation, a licensed clinician can take a history and talk through what may or may not be appropriate. Kindr Care patient intake is open now.
This article is not legal advice. Check bill or coverage questions with official sources, your insurer, or a qualified advisor.
This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.
Sources
- Etsey M, Manohar R, Mansour A, Liszak L, Oppong C, Raafati S, Wells K, Price V, Patel VJ, Lazar T, Marshall AL, Thachil R, Clark B, Gebhard R, on behalf of the AMWA Gender Equity Task Force, "American Medical Women's Association's commitment to advancing menopausal health equity and awareness," Frontiers in Reproductive Health 8:1867746, published July 3, 2026 — www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2026.1867746/full
- American Medical Women's Association, "AMWA Publishes New Position Paper on Menopause Equity," November 18, 2026 — amwa-doc.org/news/amwa-publishes-new-position-paper-on-menopause-equity
- Alex Hsuan Tsui, "B.C. launches first-of-its-kind professorship in menopause research and education," UBC Faculty of Medicine, November 18, 2026 — www.med.ubc.ca/byline-date-only/b-c-launches-first-of-its-kind-professorship-in-menopause-research-and-education
- BC Women's Health Foundation, "BC launches first-of-its-kind jointly held professorship in menopause research and education," GlobeNewswire, November 18, 2026 — www.globenewswire.com/news-release/2026/11/18/3405849/0/en/bc-launches-first-of-its-kind-jointly-held-professorship-in-menopause-research-and-education.html
- ACOG, "ACOG Expands Recommendations for Management of Menopause Symptoms," October 15, 2026 — www.acog.org/news/2026/10/acog-expands-recommendations-for-management-of-menopause-symptoms
- ACOG Clinical Practice Guideline 13, "Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms" — www.acog.org/clinical/guidance/clinical-practice-guideline/2026/11/management-of-menopause-related-vasomotor-sleep-and-mood-symptoms
- WBUR Here & Now, "New guidelines prioritize hormone therapy for menopause symptoms," November 17, 2026 — www.wbur.org/hereandnow/2026/11/17/menopause-symptoms-hormones
- Penn State Health News, "The Medical Minute: New menopause guidelines support hormone replacement for hot flashes and night sweats," November 18, 2026 — pennstatehealthnews.org/2026/11/the-medical-minute-new-menopause-guidelines-support-hormone-replacement-for-hot-flashes-and-night-sweats
- Vahratian A, Clayton JA, "Characteristics of Women Ages 40–60 with Menopausal Symptoms: United States, 2025," NCHS Data Brief No. 575, October 2026 — www.cdc.gov/nchs/products/databriefs/db575.htm
- 988 Suicide & Crisis Lifeline — 988lifeline.org
Medically reviewed by Kindr Health Clinical Team
Last updated: November 19, 2026
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Is HRT safe?Journal
- When to start HRTJournal
- Menopause HRT serviceMedication
- Complete menopause guideJournal
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.